Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Relacorilant - Corcept Therapeutics

Drug Profile

Relacorilant - Corcept Therapeutics

Alternative Names: CORT-125134

Latest Information Update: 20 Nov 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Corcept Therapeutics
  • Class Antineoplastics; Small molecules
  • Mechanism of Action Glucocorticoid receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Pancreatic cancer; Cushing syndrome
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Cushing syndrome
  • Phase II Fallopian tube cancer; Ovarian cancer; Peritoneal cancer
  • Phase I/II Solid tumours
  • Phase I Prostate cancer

Most Recent Events

  • 07 Nov 2019 Corcept Therapeutics announces intention to submit NDA to the US FDA for Cushing syndrome in the fourth quarter of 2021
  • 07 Nov 2019 Relacorilant receives Orphan Drug status for Pancreatic cancer in European Union
  • 07 Nov 2019 Corcept Therapeutics plans a phase III trial for Cushing's syndrome in the Europe and the US in the first quarter of 2020
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top